What do Lung cancer patients in which the disease has spread, feel should be meaningful benefit from chemotherapy drugs given for controlling their cancer-A survey
Not Applicable
- Conditions
- Health Condition 1: C34- Malignant neoplasm of bronchus andlung
- Registration Number
- CTRI/2022/01/039563
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with metastatic lung cancer being treated currently with cytotoxic palliative chemotherapy +/- targeted therapy.
2. Patients currently on first line palliative chemotherapy who have completed at least 2 cycles
3. Patients who are not more than 6 months into their course of palliative chemotherapy and intend to continue chemotherapy
Exclusion Criteria
1. Patients who have completed the planned chemotherapy.
2. Patients with brain metastases or other conditions which affects cognition and the ability to complete the survey/interview.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To estimate the number of months of improvement in survival that patients consider enough benefit for palliative chemotherapy over best supportive carein patients with metastatic lung cancers <br/ ><br>2. To evaluate factors influencing the patient preference of treatment <br/ ><br>3.Subset analysis will be performed to see variation in survival thresholds for patients on cytotoxic chemotherapy (+/targeted therapy) and targeted therapy alone.Timepoint: At recruitment baseline evaluation and no furthur follow up <br/ ><br>
- Secondary Outcome Measures
Name Time Method ot applicableTimepoint: Not applicable